{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T08:43:07Z","timestamp":1742978587074,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":26,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071630358"},{"type":"electronic","value":"9781071630365"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3036-5_23","type":"book-chapter","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T13:24:05Z","timestamp":1680182645000},"page":"327-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vivo Evaluation of Exon 51 Skipping in hDMD\/Dmd-null Mice"],"prefix":"10.1007","author":[{"given":"Narin","family":"Sheri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00275183","volume":"66","author":"H Moser","year":"1984","unstructured":"Moser H (1984) Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 66:17\u201340. https:\/\/doi.org\/10.1007\/BF00275183","journal-title":"Hum Genet"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/364725a0","volume":"364","author":"GA Cox","year":"1993","unstructured":"Cox GA, Cole NM, Matsumura K et al (1993) Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 364:725\u2013729. https:\/\/doi.org\/10.1038\/364725a0","journal-title":"Nature"},{"key":"23_CR4","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498\u2013506","journal-title":"Am J Hum Genet"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395. https:\/\/doi.org\/10.1016\/0888-7543(88)90113-9","journal-title":"Genomics"},{"key":"23_CR6","doi-asserted-by":"publisher","unstructured":"Di Fusco D, Dinallo V, Marafini I et al (2019) Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease. Front Pharmacol 10. https:\/\/doi.org\/10.3389\/fphar.2019.00305","DOI":"10.3389\/fphar.2019.00305"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/adna.2.1.15425","volume":"2","author":"C Brolin","year":"2011","unstructured":"Brolin C, Shiraishi T (2011) Antisense mediated exon skipping therapy for Duchenne muscular dystrophy (DMD). Artif DNA PNA XNA 2:6\u201315. https:\/\/doi.org\/10.4161\/adna.2.1.15425","journal-title":"Artif DNA PNA XNA"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y et al (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12:1141\u20131152. https:\/\/doi.org\/10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci 102:198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52\u2013deficient mdx mouse. Mol Ther 18:1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Mol Ther"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscular Dis 4:199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscular Dis"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213","journal-title":"Methods Mol Biol"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","volume":"12","author":"JJ Dowling","year":"2016","unstructured":"Dowling JJ (2016) Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat Rev Neurol 12:675\u2013676. https:\/\/doi.org\/10.1038\/nrneurol.2016.180","journal-title":"Nat Rev Neurol"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Design Dev Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Design Dev Ther"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A (2020) Golodirsen: first approval. Drugs 80:329\u2013333. https:\/\/doi.org\/10.1007\/s40265-020-01267-2","journal-title":"Drugs"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Viltolarsen: first approval. Drugs 80:1027\u20131031. https:\/\/doi.org\/10.1007\/s40265-020-01339-3","journal-title":"Drugs"},{"key":"23_CR17","unstructured":"U.S. Food and Drug Administration FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation. Accessed 24 Aug 2020"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2020.0845","volume":"30","author":"A Aartsma-Rus","year":"2020","unstructured":"Aartsma-Rus A, Corey DR (2020) The 10th oligonucleotide therapy approved: Golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther 30:67\u201370. https:\/\/doi.org\/10.1089\/nat.2020.0845","journal-title":"Nucleic Acid Ther"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/184393","volume":"2011","author":"A Nakamura","year":"2011","unstructured":"Nakamura A, Takeda S (2011) Mammalian models of Duchenne muscular dystrophy: pathological characteristics and therapeutic applications. J Biomed Biotechnol 2011:1\u20138. https:\/\/doi.org\/10.1155\/2011\/184393","journal-title":"J Biomed Biotechnol"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, Hakim CH, McIntosh MA et al (2015) Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech 8:195\u2013213. https:\/\/doi.org\/10.1242\/dmm.018424","journal-title":"Dis Model Mech"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ymthe.2004.05.031","volume":"10","author":"M Bremmer-Bout","year":"2004","unstructured":"Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ et al (2004) Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10:232\u2013240. https:\/\/doi.org\/10.1016\/j.ymthe.2004.05.031","journal-title":"Mol Ther"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25:2561\u20132572. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JND-170218","volume":"4","author":"CS Young","year":"2017","unstructured":"Young CS, Mokhonova E, Quinonez M et al (2017) Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR\/Cas9 gene editing therapy. J Neuromuscular Dis 4:139\u2013145. https:\/\/doi.org\/10.3233\/JND-170218","journal-title":"J Neuromuscular Dis"},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"e0193289","DOI":"10.1371\/journal.pone.0193289","volume":"13","author":"M Veltrop","year":"2018","unstructured":"Veltrop M, van Vliet L, Hulsker M et al (2018) A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLoS One 13:e0193289. https:\/\/doi.org\/10.1371\/journal.pone.0193289","journal-title":"PLoS One"},{"key":"23_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/genes11030342","volume":"11","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Nguyen Q, Dzierlega K et al (2020) CRISPR-generated animal models of duchenne muscular dystrophy. Genes (Basel) 11:342. https:\/\/doi.org\/10.3390\/genes11030342","journal-title":"Genes (Basel)"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R et al (2017) Development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther 27:251\u2013259. https:\/\/doi.org\/10.1089\/nat.2017.0682","journal-title":"Nucleic Acid Ther"}],"container-title":["Methods in Molecular Biology","Skeletal Muscle Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3036-5_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T13:29:53Z","timestamp":1680182993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3036-5_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071630358","9781071630365"],"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3036-5_23","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"31 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}